Larimar Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Larimar Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to 2023.
  • Larimar Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $162M.
  • Larimar Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $30K.
  • Larimar Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $75.3M, a 278% increase from 2021.
  • Larimar Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $19.9M, a 78.8% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $30K* -$75.2M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 $75.3M +$55.4M +278% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $19.9M -$73.7M -78.8% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 $93.6M +$74.2M +383% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-25
2019 $19.4M -$47.5M -71% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-04
2018 $66.9M +$50.3M +304% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-05
2017 $16.6M +$19.3M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-05
2016 -$2.72M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.